Key Takeaways:
- Novavax (NVAX, Financial) experienced a significant stock price increase following the FDA's request for additional clinical data.
- Wall Street analysts see potential upside for NVAX, with a high price target of $25.00 per share.
- GuruFocus estimates suggest a potential downside, with a GF Value indicating a lower fair market price.
Novavax Inc. (NASDAQ: NVAX) witnessed a remarkable stock surge of 17.1%, reaching $7.32. This jump came after the company received an official request from the U.S. Food and Drug Administration (FDA) for further clinical data concerning its COVID-19 vaccine application. Novavax is poised to address the request swiftly as it aims to achieve full regulatory approval, pending the FDA's satisfaction of provided criteria.
Analysts' Price Target for Novavax
Currently, six analysts have presented their one-year price targets for Novavax Inc. (NVAX, Financial), averaging out to $17.33. Their projections vary, with the highest estimate reaching $25.00 and the lowest at $9.00. This average target price hints at a potential upside of 132.04% from the present share price of $7.47. For more comprehensive estimates, visit the Novavax Inc (NVAX) Forecast page.
Brokerage Recommendations
From the insights gathered from seven brokerage firms, Novavax Inc. (NVAX, Financial) holds an average brokerage recommendation of 2.3. This rating marks the stock as "Outperform," based on a scale where 1 indicates a "Strong Buy" and 5 signifies a "Sell."
GuruFocus Valuation Insights
According to GuruFocus estimates, the projected GF Value of Novavax Inc. (NVAX, Financial) within a year stands at $5.64. This suggests a potential downside of approximately 24.5% from the current price of $7.47. The GF Value represents GuruFocus' appraisal of the fair trading value of the stock, derived from historical trading multiples, previous business growth, and forecasted business performance. For detailed insights, refer to the Novavax Inc (NVAX) Summary page.
